Durable response to nivolumab in combination with regional hyperthermia in a patient with PD-L1-negative metastatic head and neck squamous cell carcinoma

被引：0

作者：

Luc M. Berclaz ^{[1
]}

Anton Burkhard-Meier ^{[2
]}

Axel Lechner ^{[1
]}

Michael Völkl ^{[3
]}

Sinan E. Güler ^{[1
]}

Sultan Abdel-Rahman ^{[1
]}

Sina Mansoorian ^{[1
]}

Wolfgang G. Kunz ^{[4
]}

Thomas Knösel ^{[5
]}

Martin Canis ^{[6
]}

Michael von Bergwelt-Baildon ^{[3
]}

Rolf D. Issels ^{[1
]}

Dorit Di Gioia ^{[2
]}

Lars H. Lindner ^{[1
]}

机构：

[1] University Hospital,Department of Internal Medicine III

[2] LMU Munich,Deparment of Otorhinolaryngology

[3] German Cancer Consortium (DKTK),Department of Radiation Oncology

[4] Partner Site Munich,Department of Radiology

[5] University Hospital,Institute of Pathology

[6] LMU Munich,undefined

[7] University Hospital,undefined

[8] LMU Munich,undefined

[9] University Hospital,undefined

[10] LMU Munich,undefined

[11] LMU Munich,undefined

来源：

Cancer Immunology, Immunotherapy | / 74卷 / 6期

关键词：

Immunotherapy; Immune checkpoint inhibitors; Head and neck cancer; Regional hyperthermia;

D O I：

10.1007/s00262-025-04029-9

中图分类号：

学科分类号：

摘要：

We report a long-lasting response to the immune checkpoint inhibitor nivolumab in combination with regional hyperthermia (RHT) in a patient with recurrent metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) and negative programmed death ligand 1 (PD-L1) expression. Treatment was well tolerated with no local side effects. Tumor-related symptoms in the orbital and masticator area gradually decreased under treatment with nivolumab and RHT. Over the course of treatment, magnetic resonance imaging (MRI) showed a local tumor control in the heated tumor areas, while metastatic lesions developed in areas outside of the RHT field. This is the first case report demonstrating the feasibility and clinical potential of the addition of RHT in this patient collective with poor outcomes and low response rates to immune checkpoint inhibitors. RHT might be an additional tool to activate an immunogenic milieu responsive to immune checkpoint inhibitors.

引用

共 50 条

[41] Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma
de Ruiter, E.
Mulder, F.
Speel, E.
van den Hout, M.
de Roest, R.
Bloemena, E.
Devriese, L.
Willems, S.
VIRCHOWS ARCHIV, 2019, 475 : S90 - S91
[42] Determining PD-L1 expression in head and neck squamous cell carcinoma using immunohistochemistry
Mishra, Prabha S.
Sidhu, Avnit
Dwivedi, Gunjan
Mulajker, Deepak S.
Awasthi, Shivali
INDIAN JOURNAL OF CANCER, 2022, 59 (04) : 474 - 479
[43] Performance of Different Diagnostic PD-L1 Clones in Head and Neck Squamous Cell Carcinoma
Ribbat-Idel, Julika
Dressler, Franz F.
Krupar, Rosemarie
Watermann, Christian
Paulsen, Finn-Ole
Kuppler, Patrick
Klapper, Luise
Offermann, Anne
Wollenberg, Barbara
Rades, Dirk
Laban, Simon
Reischl, Markus
Bruchhage, Karl-Ludwig
Idel, Christian
Perner, Sven
FRONTIERS IN MEDICINE, 2021, 8
[44] Prognostic significance of PD-L1 expression in patients with head and neck squamous cell carcinoma
Peng, C.
Gu, X.
Gao, X. S.
Li, X.
Qin, S.
Ma, M.
Cui, M.
Xie, M.
Bai, Y.
RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S267 - S268
[45] Assessing PD-L1 Expression in Head and Neck Squamous Cell Carcinoma: Trials and Tribulations
Ruben Bill
William C. Faquin
Sara I. Pai
Head and Neck Pathology, 2023, 17 : 969 - 975
[46] Assessing PD-L1 Expression in Head and Neck Squamous Cell Carcinoma: Trials and Tribulations
Bill, Ruben
Faquin, William C.
Pai, Sara I.
HEAD & NECK PATHOLOGY, 2023, 17 (04): : 969 - 975
[47] Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma
de Ruiter, E. J.
Mulder, F.
Speel, E.
van den Hout, M.
de Roest, R.
Bloemena, E.
Devriese, L.
Willems, S.
EUROPEAN JOURNAL OF CANCER, 2019, 110 : S20 - S20
[48] Prognostic Significance of PD-L1 Expression in Patients with Head and Neck Squamous Cell Carcinoma
Peng, C.
Gao, X. S.
Gu, X.
Ma, M.
Li, X.
Qi, X.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E365 - E365
[49] Challenges facing pathologists evaluating PD-L1 in head & neck squamous cell carcinoma
Girolami, Ilaria
Pantanowitz, Liron
Barberis, Massimo
Paolino, Gaetano
Brunelli, Matteo
Vigliar, Elena
Munari, Enrico
Satturwar, Swati
Troncone, Giancarlo
Eccher, Albino
JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2021, 50 (09) : 864 - 873
[50] Neoadjuvant PD-1/PD-L1 axis blockade for patients with head and neck squamous cell carcinoma
Huang, Shuang
Xiong, Chuang
Tan, Kui
AMERICAN JOURNAL OF OTOLARYNGOLOGY, 2023, 44 (06)

← 1 2 3 4 5 →